EMARDD is short for early-onset myopathy, areflexia, respiratory distress and dysphagia. It is a rare congenital myopathy linked to biallelic pathogenic variants in the MEGF10 gene.
The condition usually begins in infancy or early childhood. It mainly affects muscle strength, reflexes, breathing and swallowing, although the severity can vary between individuals.
Name
The name describes the main features:
- early-onset myopathy, meaning muscle disease beginning early in life
- areflexia, meaning reduced or absent reflexes
- respiratory distress, often linked to weakness of the diaphragm and breathing muscles
- dysphagia, meaning difficulty swallowing
EMARDD is also described as MEGF10-related myopathy. Some sources describe a milder variant in which symptoms are less severe or progress more slowly.
Cause and Inheritance
EMARDD is caused by pathogenic variants in both copies of MEGF10. The inheritance pattern is autosomal recessive, so parents are usually unaffected carriers when a child is affected.
MEGF10 is involved in muscle development and repair. When the gene is not working properly, muscle function can be impaired from early life.
EMARDD should not be confused with TRPV4-related neuromuscular disorders. TRPV4 can cause other neuromuscular and skeletal conditions, but the recognised cause of EMARDD is MEGF10.
Symptoms
Typical features include:
- early muscle weakness
- low muscle tone
- reduced or absent deep tendon reflexes
- breathing difficulty
- feeding and swallowing problems
- scoliosis
- joint contractures
- delayed motor milestones
Some affected children have reduced fetal movement before birth. Muscle biopsy may show myopathic or dystrophic changes.
The breathing problems are especially important. Some affected people require ventilatory support, and severe cases may become ventilator-dependent early in life.
Diagnosis
Diagnosis is based on clinical features, neurological and muscle assessment, respiratory assessment and genetic testing. MEGF10 testing can confirm the diagnosis when the clinical picture fits.
Other tests may include muscle biopsy, electromyography, respiratory function tests, swallowing assessment and imaging for scoliosis or joint problems.
Because EMARDD is rare, diagnosis may involve a specialist neuromuscular team and comparison with other congenital myopathies.
Management
Management is supportive and usually involves several specialists. Care may include:
- respiratory monitoring and ventilatory support
- feeding and swallowing support
- physiotherapy
- occupational therapy
- orthopaedic care for scoliosis and contractures
- nutrition support
- genetic counselling for the family
There is no established cure. Treatment aims to protect breathing, maintain function where possible, reduce complications and support quality of life.
Outlook
The outlook varies. Severe cases can cause major breathing problems in infancy or childhood. Milder cases may follow a longer course with more gradual loss of strength.
The variability is one reason detailed clinical assessment matters. People with the same broad diagnosis may have different levels of mobility, respiratory need and daily support.
Research
Research on EMARDD is limited because the condition is rare. Published case reports and small series help define the MEGF10 disease spectrum, the range of severity and the practical care needs of affected people.
See Also
References
Discussion log
Use comments for sourcing notes, corrections, and disputed details.
No comments yet.